Status:
COMPLETED
Responses to COVID-19 Vaccination in Patients With Cancer
Lead Sponsor:
Hellenic Cooperative Oncology Group
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study that will prospectively record and monitor responses and clinical outcomes of patients with cancer after covid-19 vaccination, including measurements of antibody titers ...
Detailed Description
It is well recognised that patients with cancer are at an increased risk of severe COVID-19 disease and should be at high prioritisation for vaccination against SARS-CoV-2. In Greece the vaccination o...
Eligibility Criteria
Inclusion
- Patients with solid tumours and potentially immunocompromised, ie. currently with active disease and/or undergoing active antineoplastic therapy of any type (chemotherapy, immunotherapy, biologic therapy, targeted therapy) that will be vaccinated for covid-19 within the National Program of Vaccination
- patients must sign informed consent for their data monitoring and also for serum antibody titers to covid-19 vaccination measured in three timepoints, prior to 1st dose and 1 and 3 months post completion of two doses
Exclusion
- patients with haematological malignancies are excluded
- patients with prior diagnosis of cancer and now on follow-up without active disease are excluded
- patients on adjuvant hormonal therapy are excluded
Key Trial Info
Start Date :
January 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 20 2022
Estimated Enrollment :
332 Patients enrolled
Trial Details
Trial ID
NCT04745377
Start Date
January 12 2021
End Date
May 20 2022
Last Update
August 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Metropolitan Hospital
Athens, Attica, Greece, 18547